CLINICAL STUDIES
Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial
Kenneth A. Ault, MD*,
Christopher P. Cannon, MD ,
Jane Mitchell*,
John McCahan*,
Russell P. Tracy, PhD ,
William F. Novotny, MD ,
James D. Reimann, PhD and
Eugene Braunwald, MD
* Maine Medical Center Research Institute, South Portland, Maine, USA
University of Vermont School of Medicine, Burlington, Vermont, USA
Genentech Inc., South San Francisco, California, USA
Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Manuscript received June 29, 1998;
revised manuscript received October 9, 1998,
accepted November 16, 1998.
Reprint requests and correspondence: Dr. Kenneth A. Ault, MMCRI, 125 John Roberts Road, Suite #8, South Portland, Maine 04106
aultk{at}mail.mmc.org
OBJECTIVES
This study was designed to determine the magnitude and time course of platelet activation during therapy of acute coronary syndromes with an oral platelet antagonist.
BACKGROUND
Platelet activation and aggregation are central to the pathogenesis of the acute coronary syndromes (ACS). However, few data are available on levels of platelet activation over time in patients with ACS, especially in the setting of chronic glycoprotein (GP) IIb/IIIa inhibition.
METHODS
The Thrombolysis in Myocardial Infarction (TIMI) 12 trial was a phase II, double-blind trial evaluating the effects of sibrafiban, an oral, selective antagonist of the platelet glycoprotein IIb/IIIa receptor in patients stabilized after an ACS. A subset of 90 of the 329 patients in the study had measurement of platelet activation as assessed by the expression of platelet associated P-Selectin on days 0, 7 and 28. Platelet activation was measured in blood samples that were fixed either immediately (spontaneous activation) or after 5 minute incubation with 0, 1 µM or 5 µM ADP in order to assess platelet responsiveness to very low or moderate stimulation.
RESULTS
At baseline there was a significant elevation of spontaneous platelet activation as compared to samples obtained from normal donors or from patients who did not have acute coronary syndromes (ACS patients 27.6 ± 18.7%, Normal controls 8.5 ± 4.4%, Patient controls 10.9 ± 7.1%, p < 0.005 for both). In addition, there was a significant decrease in the levels of platelet activation with time during the 28 days of treatment with sibrafiban. Nevertheless, even on day 28, the TIMI-12 patients continued to show elevated platelet activation in comparison to the control groups (p < 0.05 for both).
CONCLUSIONS
These results suggest that platelets remain activated long after clinical stabilization post ACS. Although platelet activation decreased after one month of oral GPIIb/IIIa inhibition, levels remained higher than normal, suggesting the need for long-term antiplatelet therapy following ACS.
|
Abbreviations and Acronyms
| | ACS | = acute coronary syndromes | | ADP | = adenosine diphosphate | | GP | = glycoprotein | | MI | = myocardial infarction | | PTCA | = percutaneous transluminal coronary angioplasty | | PBS | = phosphate buffered saline | | TIMI | = Thrombolysis in Myocardial Infarction |
|
This article has been cited by other articles:
|
|
|
|
 
L. O. Jensen, M. Maeng, P. Thayssen, A. Kaltoft, H. H. Tilsted, M. Bottcher, J. F. Lassen, K. N. Hansen, L. R. Krusell, K. Rasmussen, et al.
Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction
Circ Cardiovasc Intervent,
December 1, 2008;
1(3):
176 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
111 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ndrepepa, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, M. Seyfarth, J. Pache, J. Dirschinger, et al.
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial
Eur. Heart J.,
February 2, 2008;
29(4):
455 - 461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, A. Dibra, C. Spaulding, G. J. Laarman, M. Menichelli, M. Valgimigli, E. Di Lorenzo, C. Kaiser, I. Tierala, J. Mehilli, et al.
Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction
Eur. Heart J.,
November 2, 2007;
28(22):
2706 - 2713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Aschbacher, R. von Kanel, P. J. Mills, S. Hong, S. K. Roepke, B. T. Mausbach, T. L. Patterson, M. G. Ziegler, J. E. Dimsdale, S. Ancoli-Israel, et al.
Combination of Caregiving Stress and Hormone Replacement Therapy is Associated With Prolonged Platelet Activation to Acute Stress Among Postmenopausal Women
Psychosom Med,
November 1, 2007;
69(9):
910 - 917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mahmud, J. J. Cavendish, S. Tsimikas, L. Ang, C. Nguyen, G. Bromberg-Marin, G. Schnyder, S. Keramati, V. Palakodeti, W. F. Penny, et al.
Elevated Plasma Fibrinogen Level Predicts Suboptimal Response to Therapy With Both Single- and Double-Bolus Eptifibatide During Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
June 5, 2007;
49(22):
2163 - 2171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gawaz and T. Geisler
Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma: reply
Eur. Heart J.,
March 1, 2007;
28(5):
641 - 642.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lupia, O. Bosco, S. Bergerone, A. E. Dondi, A. Goffi, E. Oliaro, M. Cordero, L. Del Sorbo, G. Trevi, and G. Montrucchio
Thrombopoietin Contributes to Enhanced Platelet Activation in Patients With Unstable Angina
J. Am. Coll. Cardiol.,
December 5, 2006;
48(11):
2195 - 2203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Leger, L. Covic, and A. Kuliopulos
Protease-Activated Receptors in Cardiovascular Diseases
Circulation,
September 5, 2006;
114(10):
1070 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, J. Mehilli, F.-J. Neumann, F. Dotzer, J. ten Berg, H. Bollwein, I. Graf, M. Ibrahim, J. Pache, M. Seyfarth, et al.
Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial
JAMA,
April 5, 2006;
295(13):
1531 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Leger, S. L. Jacques, J. Badar, N. C. Kaneider, C. K. Derian, P. Andrade-Gordon, L. Covic, and A. Kuliopulos
Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis
Circulation,
March 7, 2006;
113(9):
1244 - 1254.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Xu, Y. Huo, M.-C. Toufektsian, S. I. Ramos, Y. Ma, A. D. Tejani, B. A. French, and Z. Yang
Activated platelets contribute importantly to myocardial reperfusion injury
Am J Physiol Heart Circ Physiol,
February 1, 2006;
290(2):
H692 - H699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-S. Wang, Y.-S. Li, J.-C. Chen, and Y.-W. Chen
Effects of Exercise Training and Deconditioning on Platelet Aggregation Induced by Alternating Shear Stress in Men
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2005;
25(2):
454 - 460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J R S Day, I S Malik, A Weerasinghe, M Poullis, I Nadra, D O Haskard, K M Taylor, and R C Landis
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention
Heart,
July 1, 2004;
90(7):
794 - 799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Frazier
Novel Predictors of Acute Coronary Syndrome Outcomes
Biol Res Nurs,
July 1, 2003;
5(1):
30 - 36.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Tsiara, M. Elisaf, I. A. Jagroop, and D. P. Mikhailidis
Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity?
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2003;
9(3):
177 - 190.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Mirabet, D. Garcia-Dorado, J. Inserte, J. A. Barrabes, R.-M. Lidon, B. Soriano, M. Azevedo, F. Padilla, L. Agullo, M. Ruiz-Meana, et al.
Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts
Am J Physiol Heart Circ Physiol,
September 1, 2002;
283(3):
H1134 - H1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, D. J. Moliterno, M. Bertrand, F.-J. Neumann, H. C. Herrmann, E. R. Powers, C. L. Grines, J. W. Moses, D. J. Cohen, E. A. Cohen, et al.
Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial*
Circulation,
May 21, 2002;
105(20):
2347 - 2354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Shebuski and K. S. Kilgore
Role of Inflammatory Mediators in Thrombogenesis
J. Pharmacol. Exp. Ther.,
March 1, 2002;
300(3):
729 - 735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N T Mulvihill and J B Foley
Inflammation in acute coronary syndromes
Heart,
March 1, 2002;
87(3):
201 - 204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R Prieto, H. Ma, R. Huang, G. Khan, K. A Schwartz, E. E Hage-Korban, A. H Schmaier, J. M Davis, A. A.K Hasan, and G. S Abela
Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury
Cardiovasc Res,
March 1, 2002;
53(4):
984 - 992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Michelson, M. R. Barnard, L. A. Krueger, C. R. Valeri, and M. I. Furman
Circulating Monocyte-Platelet Aggregates Are a More Sensitive Marker of In Vivo Platelet Activation Than Platelet Surface P-Selectin: Studies in Baboons, Human Coronary Intervention, and Human Acute Myocardial Infarction
Circulation,
September 25, 2001;
104(13):
1533 - 1537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-A. Weber and K. Schror
Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics
Blood,
September 1, 2001;
98(5):
1619 - 1621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes
Circulation,
April 3, 2001;
103(13):
1727 - 1733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Chew, D. L. Bhatt, S. Sapp, and E. J. Topol
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists : A Meta-Analysis of Phase III Multicenter Randomized Trials
Circulation,
January 16, 2001;
103(2):
201 - 206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Marso, D. L. Bhatt, M. T. Roe, P. L. Houghtaling, M. Labinaz, N. S. Kleiman, C. Dyke, M. L. Simmoons, R. M. Califf, R. A. Harrington, et al.
Enhanced Efficacy of Eptifibatide Administration in Patients With Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting
Circulation,
December 12, 2000;
102(24):
2952 - 2958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Akkerhuis, K.-L. Neuhaus, R. G. Wilcox, A. Vahanian, J.-L. Boland, J. Hoffmann, T. Baardman, G. Nehmiz, U. Roth, A. P. J. Klootwijk, et al.
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study
Eur. Heart J.,
December 2, 2000;
21(24):
2042 - 2055.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Cox, R. Smith, M. Quinn, P. Theroux, P. Crean, and D. J. Fitzgerald
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
J. Am. Coll. Cardiol.,
November 1, 2000;
36(5):
1514 - 1519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Merten, T. Chow, J. D. Hellums, and P. Thiagarajan
A New Role for P-Selectin in Shear-Induced Platelet Aggregation
Circulation,
October 24, 2000;
102(17):
2045 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. T. Mulvihill, J. B. Foley, R. Murphy, P. Crean, and M. Walsh
Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction
J. Am. Coll. Cardiol.,
October 1, 2000;
36(4):
1210 - 1216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Helft, J. I. Osende, S. G. Worthley, A. G. Zaman, O. J. Rodriguez, E. I. Lev, M. E. Farkouh, V. Fuster, J. J. Badimon, and J. H. Chesebro
Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2000;
20(10):
2316 - 2321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol
Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
JAMA,
September 27, 2000;
284(12):
1549 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Moshfegh, M. Redondo, F. Julmy, W. A. Wuillemin, M. U. Gebauer, A. Haeberli, and B. J. Meyer
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy
J. Am. Coll. Cardiol.,
September 1, 2000;
36(3):
699 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Merlini, D. Ardissino, R. D. Rosenberg, E. Colombi, P. Agricola, L. Oltrona, F. Ottani, M. Galvani, K. A. Bauer, B. Bottasso, et al.
In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2000;
20(9):
2162 - 2166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Mousa, J. M. Bozarth, M. S. Forsythe, and A. Slee
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels
Cardiovasc Res,
September 1, 2000;
47(4):
819 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Cannon, C. H. McCabe, R. G. Wilcox, A. Langer, A. Caspi, P. Berink, J. Lopez-Sendon, J. Toman, A. Charlesworth, R. J. Anders, et al.
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial
Circulation,
July 11, 2000;
102(2):
149 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Coulter, C. P. Cannon, K. A. Ault, E. M. Antman, F. Van de Werf, A. A. J. Adgey, C. M. Gibson, R. P. Giugliano, M. A. Mascelli, J. Scherer, et al.
High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14
Circulation,
June 13, 2000;
101(23):
2690 - 2695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. O'Neill, P. Serruys, M. Knudtson, G.-A. van Es, G. C. Timmis, C. van der Zwaan, J. Kleiman, J. Gong, E. B. Roecker, R. Dreiling, et al.
Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization
N. Engl. J. Med.,
May 4, 2000;
342(18):
1316 - 1324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
